JP2017517506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517506A5 JP2017517506A5 JP2016568497A JP2016568497A JP2017517506A5 JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5 JP 2016568497 A JP2016568497 A JP 2016568497A JP 2016568497 A JP2016568497 A JP 2016568497A JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001534P | 2014-05-21 | 2014-05-21 | |
| US62/001,534 | 2014-05-21 | ||
| PCT/US2015/031081 WO2015179236A1 (en) | 2014-05-21 | 2015-05-15 | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517506A JP2017517506A (ja) | 2017-06-29 |
| JP2017517506A5 true JP2017517506A5 (enExample) | 2018-07-12 |
Family
ID=53284562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568497A Pending JP2017517506A (ja) | 2014-05-21 | 2015-05-15 | 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10023649B2 (enExample) |
| EP (1) | EP3145956A1 (enExample) |
| JP (1) | JP2017517506A (enExample) |
| KR (1) | KR20170004006A (enExample) |
| CN (1) | CN106413751A (enExample) |
| AU (1) | AU2015264528A1 (enExample) |
| BR (1) | BR112016026993A2 (enExample) |
| CA (1) | CA2949214A1 (enExample) |
| IL (1) | IL248540A0 (enExample) |
| MX (1) | MX2016015181A (enExample) |
| RU (1) | RU2016146993A (enExample) |
| WO (1) | WO2015179236A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120198A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| BR112018014016A2 (pt) * | 2016-01-25 | 2019-02-05 | Pfizer | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| AU2017363337B2 (en) * | 2016-11-23 | 2021-07-01 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| JP6609724B1 (ja) | 2017-01-06 | 2019-11-20 | ユーティレックス カンパニー リミテッド | 抗ヒト４−１ｂｂ抗体およびその使用 |
| ES2863412T3 (es) * | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| AU2018281830B2 (en) | 2017-06-09 | 2023-11-02 | Agonox, Inc. | Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer |
| EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
| IL272159B2 (en) | 2017-08-04 | 2026-03-01 | Genmab As | PD-L1 and CD137 binding agents and their use |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| RU2020118594A (ru) | 2017-11-06 | 2021-12-09 | Рапт Терапьютикс, Инк. | Противораковые агенты |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| EP3744734A1 (en) * | 2018-01-22 | 2020-12-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof |
| CA3092002A1 (en) * | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
| EP3773720A4 (en) | 2018-04-10 | 2022-01-05 | Wuxi Biologics (Shanghai) Co. Ltd. | MONOCLONAL ANTIBODIES AGAINST HUMAN 4-1BB, METHOD OF MANUFACTURING AND USING THEREOF |
| MA52889A (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
| AU2019312200B2 (en) | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2020231809A1 (en) | 2019-05-10 | 2020-11-19 | Lyvgen Biopharma Co., Ltd. | Humanized anti-cd137 antibodies and uses thereof |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4090675A4 (en) * | 2020-01-13 | 2024-02-21 | CytoDyn Inc. | CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5-POSITIVE METASTATIC BREAST CANCER |
| US20230087164A1 (en) * | 2020-02-04 | 2023-03-23 | Genmab A/S | Antibodies for use in therapy |
| CN117964757A (zh) * | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022081572A1 (en) * | 2020-10-13 | 2022-04-21 | Board Of Regents, The University Of Texas System | Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment |
| CN116916952A (zh) * | 2020-12-04 | 2023-10-20 | 宏观基因有限公司 | HER2/neu抗体的药物组合物及其用途 |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022288058A1 (en) | 2021-06-07 | 2023-11-16 | Agonox, Inc. | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| US12240910B2 (en) | 2021-07-14 | 2025-03-04 | Genentech, Inc. | Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| CN1296960A (zh) * | 1999-11-22 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸 |
| MXPA04001894A (es) | 2001-08-31 | 2005-09-08 | Kyowa Hakko Kogyo Kk | Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo. |
| WO2004006853A2 (en) * | 2002-07-15 | 2004-01-22 | Mayo Foundation For Medical Education And Research | Treatment and prophylaxis with 4-1bb-binding agents |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| CA2588157A1 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| EP2399935A3 (en) * | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| EP1896030A1 (en) | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| AR084141A1 (es) | 2010-11-19 | 2013-04-24 | Imai Toshio | Anticuerpos neutralizadores anti-ccl20 |
-
2015
- 2015-05-15 MX MX2016015181A patent/MX2016015181A/es unknown
- 2015-05-15 CA CA2949214A patent/CA2949214A1/en not_active Abandoned
- 2015-05-15 AU AU2015264528A patent/AU2015264528A1/en not_active Abandoned
- 2015-05-15 JP JP2016568497A patent/JP2017517506A/ja active Pending
- 2015-05-15 CN CN201580027437.7A patent/CN106413751A/zh active Pending
- 2015-05-15 EP EP15727159.4A patent/EP3145956A1/en not_active Withdrawn
- 2015-05-15 BR BR112016026993A patent/BR112016026993A2/pt not_active Application Discontinuation
- 2015-05-15 RU RU2016146993A patent/RU2016146993A/ru not_active Application Discontinuation
- 2015-05-15 US US15/312,515 patent/US10023649B2/en not_active Expired - Fee Related
- 2015-05-15 WO PCT/US2015/031081 patent/WO2015179236A1/en not_active Ceased
- 2015-05-15 KR KR1020167035347A patent/KR20170004006A/ko not_active Withdrawn
-
2016
- 2016-10-27 IL IL248540A patent/IL248540A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suurs et al. | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2017516775A5 (enExample) | ||
| MX2024015039A (es) | Composiciones anti-cd24 y usos de las mismas | |
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| JP2017048208A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| BRPI0918178A8 (pt) | anticorpos monoclonais para tratamento de câncer | |
| JP2019527706A5 (enExample) | ||
| JP2015214582A5 (enExample) | ||
| JP2017505782A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| Lin et al. | Combination treatment including targeted therapy for advanced hepatocellular carcinoma | |
| JP2016510028A5 (enExample) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
| JP2016521266A5 (enExample) | ||
| JP2010209081A5 (enExample) | ||
| JP2016533366A5 (enExample) |